These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 23443136)

  • 1. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.
    Saraon P; Cretu D; Musrap N; Karagiannis GS; Batruch I; Drabovich AP; van der Kwast T; Mizokami A; Morrissey C; Jarvi K; Diamandis EP
    Mol Cell Proteomics; 2013 Jun; 12(6):1589-601. PubMed ID: 23443136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.
    Saraon P; Musrap N; Cretu D; Karagiannis GS; Batruch I; Smith C; Drabovich AP; Trudel D; van der Kwast T; Morrissey C; Jarvi KA; Diamandis EP
    J Biol Chem; 2012 Oct; 287(41):34019-31. PubMed ID: 22908226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy.
    Johansson B; Pourian MR; Chuan YC; Byman I; Bergh A; Pang ST; Norstedt G; Bergman T; Pousette A
    Prostate; 2006 Sep; 66(12):1235-44. PubMed ID: 16705742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of FAM84B during prostate cancer progression.
    Wong N; Gu Y; Kapoor A; Lin X; Ojo D; Wei F; Yan J; de Melo J; Major P; Wood G; Aziz T; Cutz JC; Bonert M; Patterson AJ; Tang D
    Oncotarget; 2017 Mar; 8(12):19218-19235. PubMed ID: 28186973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression.
    Saraon P; Trudel D; Kron K; Dmitromanolakis A; Trachtenberg J; Bapat B; van der Kwast T; Jarvi KA; Diamandis EP
    Prostate; 2014 Apr; 74(4):372-80. PubMed ID: 24311408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
    Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
    Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression.
    Tonry C; Armstrong J; Pennington SR
    Oncotarget; 2017 Feb; 8(9):14374-14394. PubMed ID: 28086232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
    Miller DR; Ingersoll MA; Chatterjee A; Baker B; Shrishrimal S; Kosmacek EA; Zhu Y; Cheng PW; Oberley-Deegan RE; Lin MF
    Free Radic Biol Med; 2019 Aug; 139():24-34. PubMed ID: 31100478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
    Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
    Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
    [No Abstract]   [Full Text] [Related]  

  • 11. Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression.
    Tonry C; Armstrong J; Pennington S
    Oncotarget; 2017 Feb; 8(9):15307-15337. PubMed ID: 28410543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
    Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
    Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.
    Khan AP; Poisson LM; Bhat VB; Fermin D; Zhao R; Kalyana-Sundaram S; Michailidis G; Nesvizhskii AI; Omenn GS; Chinnaiyan AM; Sreekumar A
    Mol Cell Proteomics; 2010 Feb; 9(2):298-312. PubMed ID: 19955085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
    Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
    Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.
    Zhang L; Yang S; Chen X; Stauffer S; Yu F; Lele SM; Fu K; Datta K; Palermo N; Chen Y; Dong J
    Mol Cell Biol; 2015 Apr; 35(8):1350-62. PubMed ID: 25645929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer cancer-associated fibroblasts with stable markers post-androgen deprivation therapy associated with tumor progression and castration resistant prostate cancer.
    Pan S; Yin R; Zhu H; Shen S; Li Z; Liu B
    Cancer Sci; 2024 Sep; 115(9):2893-2907. PubMed ID: 38970292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
    Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirtuin 5 regulates the proliferation, invasion and migration of prostate cancer cells through acetyl-CoA acetyltransferase 1.
    Guan J; Jiang X; Gai J; Sun X; Zhao J; Li J; Li Y; Cheng M; Du T; Fu L; Li Q
    J Cell Mol Med; 2020 Dec; 24(23):14039-14049. PubMed ID: 33103371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.